Chinanews.com, Beijing, April 23. The "2021 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference" opened in Beijing today. Experts and scholars from various oncology fields across the country gathered to exchange academic research results, discuss industry development trends, and witness Many guides have been updated.

Millions of guides issued in the past five years

　　In the six years since the launch of the first CSCO guideline in 2016, experts from the guideline groups of the Chinese Society of Clinical Oncology have continuously formulated guidelines for the diagnosis and treatment of common malignancies in response to practical clinical problems in their respective fields, and promoted standardized clinical diagnosis and treatment of cancer in China.

Over the past five years, a total of one million copies of the guide have been issued, and more than 800 Chinese clinical oncologists and experts have worked together to actively participate in the writing and promotion of the guide.

　　Jiang Zefei, vice chairman and secretary-general of CSCO, and professor of the Department of Oncology, General Hospital of the People’s Liberation Army, introduced that nasopharyngeal cancer, biliary malignancies, non-small cell lung cancer, ovarian cancer, differentiated thyroid cancer, colorectal cancer, hematological malignancies, and lymph will be updated this year. 23 guidelines on tumors, lymphoma in children and adolescents.

At the same time, it will publish for the first time a guide for neuroendocrine tumors, central nervous system metastases, neurotumor perioperative glucocorticoid use, prevention and treatment of cardiovascular toxicity caused by anti-tumor therapy, cancer cachexia, intrahepatic cholangiocarcinoma, and lymphoma PET- CT fascicles, tumor-related anemia, childhood and adolescent leukemia, allogeneic hematopoietic stem cell transplantation treatment of leukemia/MDS 10 guidelines.

　　The new version of the guide will be published in two batches of this guide conference and the CSCO annual meeting in September. The CSCO series of guides ushered in a bumper harvest in 2021, which is the year with the largest number of guides published and updated in the history of CSCO.

　　The innovative report format of this guideline conference is to set up special sessions according to the tumor location and disease system, and in each field, the different periods and subtypes of tumors are covered horizontally, focusing on introducing and sorting out the updated points of the new version of the CSCO guidelines.

Experts talk about guide positioning and development planning

　　Experts participating in the meeting answered questions from reporters from various aspects such as the original intention, current positioning, and development plan of the CSCO guidelines, and described the "past and present" of the CSCO guidelines.

　　Wu Yilong, chairman of the CSCO Steering Committee and a professor at Guangdong Provincial People’s Hospital, said that Chinese scholars have contributed a lot of Chinese voices internationally in recent years. Since the first CSCO lung cancer diagnosis and treatment guidelines were issued in 2016, the CSCO guidelines have been dividing the evidence categories in detail. Consider research content with Chinese characteristics and internationally recognized, so as to be based on evidence-based evidence and respect expert opinions.

　　Li Jin, chairman of the Beijing Hesco Clinical Oncology Research Foundation and professor of Shanghai Tongji Oriental Hospital, as the leader of the guidelines working group pointed out that standardized diagnosis and treatment has always been an important part of improving the efficacy and improving survival in cancer diagnosis and treatment. The diagnosis and treatment guidelines It is a good starting point for standardized treatment.

The CSCO diagnosis and treatment guidelines, while keeping up with international academic developments, better take into account China's vast geographic location and the uneven economic development of various regions, and fully consider issues such as medical insurance coverage, the availability of drugs and treatment measures.

At the same time, the CSCO guidelines will also integrate standardization and individualization, embody the concept of multidisciplinary comprehensive treatment, and play a positive role in promoting the progress of clinical practice in China.

　　CSCO Chairman of the Board of Supervisors and Professor of Harbin Institute of Hematology and Cancer Research, Ma Jun, said that with the continuous efforts of Chinese oncologists, the innovation process of Chinese oncology continues to advance, and the guidelines will also standardize their clinical applications.

Oncologists and oncologists should understand and support each other, so as to increase the enthusiasm of oncologists for innovation and ultimately benefit the majority of patients.

　　Qin Shukui, vice chairman of CSCO and professor at the General Hospital of the Eastern Theater Command, pointed out that the development of medicine has gone from empirical medicine, experimental medicine to evidence-based medicine and the stage of development to precision medicine.

The CSCO guidelines reflect the latest research progress at home and abroad, and can also standardize clinical diagnosis and treatment behavior. It is hoped that the guidelines will improve the diagnosis, treatment and research level of clinical tumors.

　　CSCO Vice Chairman, Peking University Cancer Hospital Professor Guo Jun and Chinese Academy of Medical Sciences Cancer Hospital Professor Wang Jie talked about the development and changes of immunotherapy. CSCO has a specialized immunotherapy committee and has continuously launched immunotherapy-related guidelines, especially in The guidelines on adverse reaction management are well recognized by clinicians and provide a good guide for clinical practice in the field of oncology in China.

　　When talking about patient education, Liang Jun, vice chairman of CSCO and professor at Peking University International Hospital, said that with the continuous evolution of tumor chronicity and the continuous expansion of the influence of CSCO guidelines, it is not just clinicians who need guidelines, but many Cancer patients will also buy the guide for learning and consultation.

This is an inevitable trend brought about by the characteristics of tumor diseases and social development. In the future, CSCO will uphold the concept of advancing with the times and introduce more appropriate guidelines for patient groups.

　　"There is still a lot of work to be done in this area, and a long way to go." Cheng Ying, vice chairman of CSCO and professor of Jilin Cancer Hospital, also said that guidelines for the education of cancer patients have been published internationally. If the CSCO guidelines are subsequently released for patients, the content can be changed. The adjustment is easy to understand and considers how to allow patients to communicate well with doctors. At the same time, it is also possible to consider the reasonable transmission of clinical research data to patients and their families.

　　It is reported that the two-day CSCO Guidelines Conference in 2021 will successively update and release rich and detailed guidelines, and dozens of industry experts and scholars will conduct comprehensive interpretations of the content of the guidelines in this field in 11 special sessions.

(Finish)